Grundmann, D.; Loris, E.; Marx, L. et al.
Expression of the precursor marker Sox2 in the myenteric plexus in the caecum of postnatal and adult mouseNEUROGASTROENTEROLOGY AND MOTILITY. Bd. 28. 2016 S. 51-51
Fan, Xinping; Hovinga, Johanna A. Kremer; Shirotani-Ikejima, Hiroko et al.
Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiencyINTERNATIONAL JOURNAL OF HEMATOLOGY. Bd. 103. H. 3. 2016 S. 283-291
Steven, S.; Jurk, K.; Kopp, M. et al.
Glucagon-like peptide-1 (GLP-1) reduces microvascular thrombosis, systemic inflammation and platelet activation in endotoxemic miceEUROPEAN HEART JOURNAL. Bd. 37. 2016 S. 111-112
Karbach, S.; Hoermann, N. H.; Jaeckel, S. J. et al.
Gut microbiota is important in the development of angiotensin II driven arterial hypertension and vascular dysfunction in miceCARDIOVASCULAR RESEARCH. Bd. 111. 2016 S. S53-S53
Karbach, Susanne H.; Schonfelder, Tanja; Brandao, Ines et al.
Gut Microbiota Promote Angiotensin II-Induced Arterial Hypertension and Vascular DysfunctionJOURNAL OF THE AMERICAN HEART ASSOCIATION. Bd. 5. H. 9. 2016
Ruf, Wolfram
Hemostasis keeps the stem cell niche in orderBLOOD. Bd. 128. H. 8. 2016 S. 1027-1029
von Krogh, A. S.; Quist-Paulsen, P.; Waage, A. et al.
High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidenceJOURNAL OF THROMBOSIS AND HAEMOSTASIS. Bd. 14. H. 1. 2016 S. 73-82
Barco, S.; Heuschen, C. B. B. C. M.; Salman, B. et al.
Home parenteral nutrition-associated thromboembolic and bleeding events: results of a cohort study of 236 individualsJOURNAL OF THROMBOSIS AND HAEMOSTASIS. Bd. 14. H. 7. 2016 S. 1364-1373
Barco, Stefano; Lankeit, Mareike; Binder, Harald et al.
Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban Rationale and design of the HoT-PE TrialTHROMBOSIS AND HAEMOSTASIS. Bd. 116. H. 1. 2016 S. 191-197
Barco, Stefano; Lankeit, Mareike; Binder, Harald et al.
Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial (vol 116, pg 191, 2016)THROMBOSIS AND HAEMOSTASIS. Bd. 116. H. 4. 2016 S. 775-775